Mrs Betty Lou Ball, CMSW LMHP | |
1919 S 40th St, Suite 308, Lincoln, NE 68506-5243 | |
(402) 499-9930 | |
Not Available |
Full Name | Mrs Betty Lou Ball |
---|---|
Gender | Female |
Speciality | Counselor - Mental Health |
Location | 1919 S 40th St, Lincoln, Nebraska |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1700969557 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | 640 (Nebraska) | Primary |
101YM0800X | Counselor - Mental Health | 815 (Nebraska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Betty Lou Ball, CMSW LMHP 1919 S 40th St, Suite 308, Lincoln, NE 68506-5243 Ph: (402) 499-9930 | Mrs Betty Lou Ball, CMSW LMHP 1919 S 40th St, Suite 308, Lincoln, NE 68506-5243 Ph: (402) 499-9930 |
News Archive
PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced the launch of its next generation DNA sequencing and data analysis services, to enable researchers to better explore the genomic origins of disease.
Status epilepticus (SE) is a true medical and neurologic emergency. To better understand the causes, treatment approaches and associated outcomes among SE patients, investigators at the Veterans Affairs Greater Los Angeles Healthcare System retrospectively reviewed all SE cases treated within their system over an eight year period.
A special issue on sepsis has been released by the publisher Landes Bioscience (Austin, TX USA). The articles contained in this special issue of the journal Virulence have been authored by world-class investigators and provide new insights into both the pathogen-related factors and the host defense mechanisms that lead to septic shock and contribute to its resolution or fatal outcome.
Active father figures have a key role to play in reducing behaviour problems in boys and psychological problems in young women, according to a review published in the February issue of Acta Paediatrica.
ARIAD Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).
› Verified 4 days ago